|
A Phase III, Randomized, Double-Blind, Multicenter; Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small cell Lung Cancer (ARTEMIDE-Lung04)
|
|
U26-053-2
|
|
A Phase III, Randomized, Double-Blind, Multicenter; Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small cell Lung Cancer (ARTEMIDE-Lung04)
|
|
Dr. Nathaniel Robinson
|
|
The purpose of this study is to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab (also called KEYTRUDA), a standard treatment option for metastatic NSCLC.
|
Cancer - Lung
|
|
|
Check with study contact
|
|
Jillian Mcnamara Telephone: 860-679-4581. Email: jimcnamara@uchc.edu
|
|
Enrolling/recruiting.
|
|
|